Histórico

Programa de Pós-graduação em Desenvolvimento e Inovação Tecnológica em Medicamentos é um Doutorado em Associação, criado com o conceito 4 pela CAPES. Visa formar recursos humanos aptos a atuarem na pesquisa, no desenvolvimento e na inovação tecnológica de medicamentos. O PPgDITM é constituído por uma Associação de Instituições de Ensino e Pesquisa do Brasil:

  1. Universidade Federal do Ceará – UFC;
  2. Universidade Federal da Paraíba – UFPB;
  3. Universidade Federal Rural de Pernambuco – UFRPE;
  4. Universidade Federal do Rio Grande do Norte – UFRN.

A área de concentração oferecida é a de Inovação Tecnológica em Medicamentos e as linhas de pesquisa são:

  • Desenvolvimento de Produtos e Processos Farmacêuticos
  • Tecnologias Analíticas e Produtivas
  • Ensaios Pré-clínicos e Clínicos.

O Programa de Pós-graduação em Desenvolvimento e Inovação Tecnológica em Medicamentos encontra-se sediado na UFRPE, com secretaria provisória no bloco 10 (1o andar) do prédio central da UFRPE.

Conceito CAPES e Bolsas de Estudo

O Programa possui atualmente o Conceito 4 da Capes e recebe bolsas de estudos da CAPES, CNPq e FACEPE (Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco), além de contar com estudantes estrangeiros que recebem bolsas de seus países de origem ou de organismos internacionais.

 

(Doctorate in Association, Concept 4-CAPES)

The Postgraduate Program in Technological Development and Innovation in Medicines (PPgDITM) offers a PhD doctorate course that aims to train human resources able to act in the research, development and technological innovation of medicines. The PPgDITM consists of an Association of Brazilian Teaching and Research Institutions:
1. Federal University of Ceará - UFC;
2. Federal University of Paraíba - UFPB;
3. Federal Rural University of Pernambuco - UFRPE;
4. Federal University of Rio Grande do Norte - UFRN.
Technological Innovation in Medicines is offered as a concentration area with the following research lines:
a) Product Development and Pharmaceutical Processes,
b) Analytical and Productive Technologies,
c) Pre-Clinical and Clinical Tests.
In order to allow a broad training focused on the development of innovative medicines, the doctoral program is divided into thematic areas, called training stages. Each stage of training consists of compulsory and elective courses and is planned so that the student attends compulsory courses in each of the training stages and then complements the credits with electives according to the specific nature of their thesis topic. Five stages of training were structured, namely: Chemistry/Biochemistry, Pre-clinical, Pharmaceutical, Clinical and Registration and Post-Marketing, including Technological Innovation and Intellectual Property (https://sigaa.ufrn.br/sigaa/public/programa/portal.jsf?lc=pt_BR&id=4847). Doctoral graduates should have solid knowledge in the field of pharmacy, dominating the production chain for the development of new drugs and innovative research and technology transfer in some stages of the chain: from the synthesis and prospection of new bioactive molecules to the clinical research of new drugs, to determine the efficacy and safety of these molecules and their formulation in pharmaceutical specialties.

Concentration research line: TECHNOLOGICAL INNOVATION IN PHARMACEUTICALS (1- DEVELOPMENT OF PRODUCTS AND PROCESS; 2- PRE-CLINICAL AND CLINICAL TRIALS; 3-

ANALYTICAL AND PRODUCTION TECHNOLOGIES).